miR-155通过调控PKG1影响滋养细胞生物学功能并参与子痫前期的机制探讨

doi:10.11958/20221869

天津医药 ›› 2023, Vol. 51 ›› Issue (9): 928-934.doi: 10.11958/20221869

miR-155通过调控PKG1影响滋养细胞生物学功能并参与子痫前期的机制探讨

岳巾晶¹(), 曾莹¹, 郭晓珮¹, 董越¹, 姬若楠¹, 彭瑞², 罗晓华²^,^△()

1.郑州大学第三附属医院妇产科（邮编450000）
2.郑州大学第三附属医院科研办公室（邮编450000）

收稿日期:2022-11-18 修回日期:2023-03-02 出版日期:2023-09-15 发布日期:2023-09-13
通讯作者: △E-mail：Luoxiaohua620@163.com
作者简介:岳巾晶（1997），女，硕士在读，主要从事子痫前期的诊断和治疗方面研究。E-mail：1508362194@qq.com
基金资助:
河南省科技攻关项目(202102310473)

MiR-155 affects the biological functions of trophoblastic cells through regulating cGMP-dependent kinase 1 and is involved in the mechanism of preeclampsia

YUE Jinjing¹(), ZENG Ying¹, GUO Xiaopei¹, DONG Yue¹, JI Ruonan¹, PENG Rui², LUO Xiaohua²^,^△()

1. Department of Gynaecology and Obstetrics, the Third Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China
2. Department of Scientific Research Office, the Third Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China

Received:2022-11-18 Revised:2023-03-02 Published:2023-09-15 Online:2023-09-13
Contact: △E-mail：Luoxiaohua620@163.com

岳巾晶, 曾莹, 郭晓珮, 董越, 姬若楠, 彭瑞, 罗晓华. miR-155通过调控PKG1影响滋养细胞生物学功能并参与子痫前期的机制探讨[J]. 天津医药, 2023, 51(9): 928-934.

YUE Jinjing, ZENG Ying, GUO Xiaopei, DONG Yue, JI Ruonan, PENG Rui, LUO Xiaohua. MiR-155 affects the biological functions of trophoblastic cells through regulating cGMP-dependent kinase 1 and is involved in the mechanism of preeclampsia[J]. Tianjin Medical Journal, 2023, 51(9): 928-934.

摘要/Abstract

摘要：

目的探究miR-155和环磷酸鸟苷依赖性蛋白激酶1（PKG1）在子痫前期患者胎盘组织中的表达及miR-155在核因子（NF）-κB的介导下通过抑制PKG1对滋养细胞HTR-8/SVneo功能的影响。方法收集剖宫产分娩的正常产妇（NPE组）以及子痫前期产妇（PE组）的胎盘各20个,体外培养滋养细胞HTR-8/SVneo，分为NC组、mimics组、inhibitor组、siRNA NC组、PKG1 siRNA组、siRNA+inhibitor组；用NF-κB抑制剂PDTC处理细胞，分为Control组、PDTC组、PDTC+NC组、PDTC+mimics组。采用qPCR检测胎盘和滋养细胞HTR-8/SVneo中miR-155和PKG1 mRNA的表达；Western blot检测PKG1蛋白的表达；分别采用CCK-8法、Transwell法、流式细胞术检测细胞的增殖、迁移、凋亡能力。结果 PE组胎盘组织中miR-155的表达升高，而PKG1的表达降低（P<0.05）。体外实验表明，与NC组相比，miR-155 mimics组中PKG1的表达降低，滋养细胞迁移、增殖能力减弱，凋亡能力增强，miR-155 inhibitor组中PKG1表达则升高，滋养细胞迁移、增殖能力增强，凋亡能力减弱（P<0.05）；与Control组相比，PDTC组miR-155的表达降低，滋养细胞迁移、增殖能力增强，凋亡能力减弱（P<0.05）。结论 miR-155在子痫前期中表达上调，并且可在NF-κB的介导下通过下调PKG1影响滋养细胞的增殖、迁移和凋亡。

关键词: 先兆子痫, 细胞运动, 细胞增殖, 细胞凋亡, NF-κB, miR-155, PKG1, 滋养细胞

Abstract:

Objective To investigate the expression levels of miR-155 and cGMP-dependent protein kinase 1 (PKG1) in placental tissue of patients with preeclampsia, and the effect of miR-155 on the function of trophoblasts HTR-8/SVneo by inhibiting PKG1 under the mediation of nucleus factor kappa B (NF-κB). Methods Twenty placentas were collected from normal pregnant women and pre-eclampsia pregnant women who delivered by cesarean section. In vitro trophoblasts HTR-8/SVneo were cultured and divided into the NC group, the mimics group, the inhibitor group, the siRNA NC group, the PKG1 siRNA group and the siRNA+inhibitor group. Cells were treated with NF-κB inhibitor PDTC and divided into the control group, the PDTC group, the PDTC+NC group and the PDTC+mimics group. Real-time quantitative polymerase chain reaction (qPCR) was performed to detect the expression of miR-155 and PKG1 mRNA in placentas and HTR-8/SVneo cells. Western blot assay was performed to measure the level of PKG1 protein. The cell proliferation, migration and apoptosis were assessed by CCK-8 assay, Transwell assay and flow cytometry. Results The expression of miR-155 was significantly upregulated in placental tissue of the PE group, while the expression of PKG1 decreased significantly (P<0.05). The vitro experiments showed that compared with the NC group, the expression of PKG1 was significantly reduced in the miR-155 mimics group (P<0.05). The migration and proliferation ability of trophoblast was significantly weakened, the apoptotic ability was significantly enhanced (P<0.05). The expression of PKG1 was significantly increased in the miR-155 inhibitor group, the migration and proliferation ability of trophoblast was significantly enhanced, and the apoptotic ability was significantly weakened. Compared with the control group, the expression of miR-155 was significantly reduced in the PDTC group, the migration and proliferation ability of trophoblast was significantly enhanced, and the apoptotic ability was significantly weakened (P<0.05). Conclusion Results indicate that the expression of miR-155 is upregulated in preeclampsia, and can affect proliferation, migration and apoptosis of trophoblast cells by down-regulating PKG1 mediated by NF-κB.

Key words: pre-eclampsia, cell movement, cell proliferation, apoptosis, NF-kappa B, miR-155, PKG1, trophoblast

中图分类号:

R714.244

图/表 16

表1 qPCR引物序列

Tab.1 Oligonucleotide primer sequences for qPCR

基因名称	引物序列（5′→3′）	产物大小/bp
U6	上游：CTCGCTTCGGCAGCACA	96
	下游：AACGCTTCACGAATTTGCGT	96
miR-155	上游：ACACTCCAGCTGGGTTAATGCT AATCGTGATA	60
	下游：TTAATGCTAATCGTGATAGGGG	60
GAPDH	上游：TGTTCGTCATGGGTGTGAAC	154
	下游：ATGGCATGGACTGTGGTCAT	154
PKG1	上游：AACTCCACAAATGCCAGTCG	272
	下游：GCAACTGTCCTTGCCATACT	272

表2 2组产妇一般资料比较（n=20，$\bar{x}\pm s$）

Tab.2 Comparison of clinical characteristics between the two groups of patients

组别	年龄/岁	BMI/（kg/m2）	SBP/mmHg
PE组	29.7±3.5	29.1±2.3	155.3±11.2
NPE组	31.0±3.1	28.3±1.9	107.3±6.2
t	1.187	1.193	16.756^＊＊
组别	DPB/mmHg	分娩孕周/周	胎儿出生体质量/kg
PE组	98.0±9.4	36.6±2.1	2.6±0.7
NPE组	67.8±6.3	37.0±1.8	3.0±0.5
t	11.957^＊＊	0.730	3.235^＊

表3 2组胎盘组织中miR-155及PKG1 mRNA表达水平比较（n=20，$\bar{x}\pm s$）

Tab.3 Comparison of expression levels of miR-155 and PKG1 mRNA in placental tissue between the two groups

组别	miR-155	PKG1
PE组	4.41±2.06	1.52±0.90
NPE组	2.07±0.61	4.04±2.03
t	4.782^＊＊	5.076^＊＊

图1 Western blot检测2组胎盘组织中PKG1蛋白的表达量

Fig.1 Expression of PKG1 protein in placenta of two groups detected by Western blot assay

表4 miR-155 mimics和miR-155 inhibitor处理后各组miR-155、PKG1 mRNA和蛋白水平比较（n=3，$\bar{x}\pm s$）

Tab.4 Comparison of miR-155 and PKG1 mRNA expression levels after treatment with miR-155 mimics and miR-155 inhibitor between the three groups

组别	miR-155	PKG1 mRNA	PKG1蛋白
NC组	1.00±0.07	1.00±0.23	0.49±0.10
miR-155 mimics组	12.41±1.02^a	0.41±0.03^a	0.13±0.01^a
miR-155 inhibitor组	0.29±0.02^a	2.76±0.31^a	1.19±0.07^a
F	400.478^＊＊	135.734^＊＊	185.053^＊＊

图2 Western blot检测各组滋养细胞HTR-8/SVneo中PKG1蛋白的表达 A：NC组；B：miR-155 mimics组；C：miR-155 inhibitor组。

Fig.2 Expression of PKG1 protein in each group of trophoblast HTR-8/SVneo detected by Western blot assay

表5 miR-155 mimics和miR-155 inhibitor处理后各组细胞增殖、迁移及凋亡水平的比较（n=3，$\bar{x}\pm s$）

Tab.5 Comparison of cell proliferation, migration and apoptosis after treatment with miR-155 mimics and miR-155 inhibitor between the three groups

组别	增殖能力（A₄₅₀）
组别	24 h	48 h	72 h
NC组 miR-155 mimics组 miR-155 inhibitor组	0.26±0.02 0.25±0.01^a 0.29±0.01^a	0.43±0.21 0.32±0.03^a 0.50±0.03^a	0.64±0.19 0.46±0.02^a 0.87±0.04^a
F	6.048^＊	37.327^＊＊	160.188^＊＊
组别	迁移细胞数/（个/视野）		凋亡率/%
NC组 miR-155 mimics组 miR-155 inhibitor组	124.67±11.37 64.33±10.02^a 205.33±8.02^a		11.58±1.14 17.56±1.44^a 5.80±0.54^a
F	153.205^＊＊		85.114^＊＊

图3 miR-155 mimics和miR-155 inhibitor处理后各组细胞迁移情况（×200）

Fig.3 Cell migration of each group after treatment with miR-155 mimics and miR-155 inhibitor (×200)

图4 流式细胞术检测各组细胞凋亡情况

Fig.4 Detection of apoptosis in each group detected by flow cytometry

表6 抑制PKG1的表达后各组miR-155、PKG1 mRNA和蛋白水平比较（n=3，$\bar{x}\pm s$）

Tab.6 Comparison of miR-155, PKG1 mRNA and protein levels after inhibiting the expression of PKG1 between the five groups

组别	miR-155	PKG1 mRNA	PKG1蛋白
NC组	0.99±0.01	1.02±0.04	0.21±0.04
inhibitor组	0.32±0.04^a	3.06±0.19^a	0.83±0.03^a
siRNA NC组	1.07±0.09	1.00±0.03	0.25±0.05
PKG1 siRNA组	1.04±0.08	0.25±0.04	0.10±0.00
siRNA+inhibitor组	0.65±0.07^b	0.64±0.08^b	0.34±0.00^b
F	10.933^＊	12.000^＊	67.230^＊＊

图5 Western blot检测各组滋养细胞HTR-8/SVneo中PKG1蛋白的表达 A：NC组；B：inhibitor组；C：siRNA NC组；D：PKG1 siRNA组；E：siRNA+inhibitor组。

Fig.5 Expression of PKG1 protein in each group of trophoblast HTR-8/SVneo detected by Western blot assay

表7 抑制NF-κB表达后各组细胞中miR-155、PKG1 mRNA和蛋白表达水平比较（n=3，$\bar{x}\pm s$）

Tab.7 Comparison of miR-155 mimics and miR-155 mRNA expression levels after inhibiting the expression of NF-κB between the four groups

组别	miR-155 mRNA	PKG1 mRNA	PKG1蛋白
Control组	1.00±0.03	1.01±0.13	0.35±0.02
PDTC组	0.56±0.05^a	3.24±0.23^a	1.00±0.04^a
PDTC+NC组	0.57±0.01	3.13±0.25	1.01±0.05
PDTC+ mimics组	10.11±0.28^b	0.50±0.01^b	0.11±0.03^b
F	3 233.927^＊＊	182.535^＊＊	311.788^＊＊

图6 Western blot检测各组滋养细胞HTR-8/SVneo中PKG1蛋白的表达 A：Control组；B：PDTC组；C：PDTC+NC组；D：PDTC+ mimics组。

Fig.6 Expression of PKG1 protein in each group of trophoblast HTR-8/SVneo detected by Western blot assay

表8 抑制NF-κB表达后各组细胞增殖、迁移及凋亡率比较（n=3，$\bar{x}\pm s$）

Tab.8 Comparison of cell proliferation, migration and apoptosis after inhibiting the expression of NF-κB between the four groups

组别	增殖能力（A₄₅₀）
组别	24 h	48 h	72 h
Control组	0.26±0.01	0.42±0.04	0.63±0.02
PDTC组	0.29±0.02^a	0.59±0.04^a	0.93±0.04^a
PDTC+NC组	0.30±0.03	0.53±0.03	0.90±0.06
PDTC+mimics组	0.24±0.02^b	0.33±0.01^b	0.45±0.03^b
F	6.267^＊	38.309^＊＊	104.970^＊＊
组别	迁移细胞数/（个/视野）		凋亡率/%
Control组	116.00±5.29		10.13±0.96
PDTC组	169.67±8.62^a		6.25±1.06^a
PDTC+NC组	156.67±4.17		6.59±1.09
PDTC+mimics组	64.00±6.25^b		15.56±0.06^b
F	171.173^＊＊		69.012^＊＊

图7 抑制NF-κB的表达后各组细胞迁移情况（×200）

Fig.7 Cell migration of each group after inhibiting the expression of NF-κB (×200)

图8 流式细胞术检测抑制NF-κB表达后各组细胞凋亡情况

Fig.8 Detection of apoptosis in each group after inhibition of NF-κB expression by flow cytometry

参考文献 24

[1]	IVES C W, SINKEY R, RAJAPREYAR I, et al. Preeclampsia-pathophysiology and clinical presentations:JACC state-of-the-art review[J]. J Am Coll Cardiol, 2020, 76(14):1690-1702. doi:10.1016/j.jacc.2020.08.014.
[2]	ALFAIFI A A, HEYDER R S, BIELSKI E R, et al. Megalin-targeting liposomes for placental drug delivery[J]. J Control Release, 2020, 324:366-378. doi:10.1016/j.jconrel.2020.05.033.
[3]	ZHOU Y, WANG J, WANG L, et al. Effect of compound danshen injection combined with magnesium sulfate on oxidative stress,TNF-alpha,NO,and therapeutic efficacy in severe preeclampsia[J]. Comput Intell Neurosci, 2022, 2022:9789066. doi:10.3390/biom10060953.
[4]	SHIRVANI S O, SCHERR J, KAYVANPOUR E, et al. Marathon-induced cardiac strain as model for the evaluation of diagnostic microRNAs for acute myocardial infarction[J]. J Clin Med, 2021, 11(1):5. doi:10.3390/jcm11010005.
[5]	KOLKOVA Z, HOLUBEKOVA V, GRENDAR M, et al. Association of circulating miRNA expression with preeclampsia,its onset,and severity[J]. Diagnostics (Basel), 2021, 11(3):476. doi:10.3390/diagnostics11030476.
[6]	LUO X, PAN C, GUO X, et al. Methylation mediated silencing of miR-155 suppresses the development of preeclampsia in vitro and in vivo by targeting FOXO3[J]. Mediators Inflamm, 2022, 2022:4250621. doi:10.1155/2022/4250621.
[7]	CHOI S, PARK M, KIM J, et al. TNF-alpha elicits phenotypic and functional alterations of vascular smooth muscle cells by miR-155-5p-dependent down-regulation of cGMP-dependent kinase 1[J]. J Biol Chem, 2018, 293(38):14812-14822. doi:10.1074/jbc.RA118.004220.
[8]	中华医学会妇产科学分会妊娠期高血压疾病学组. 妊娠期高血压疾病诊治指南(2020)[J]. 中华妇产科杂志, 2020, 55(4):227-238.
	Group of Hypertensive Disorders of Pregnancy,Obstetrics and Gynecology Branch of Chinese Medical Association. Guidelines for the diagnosis and treatment of hypertensive disorders during pregnancy(2020)[J]. Chin J Obstetr Gynecol, 2020, 55(4):227-238. doi:10.3760/cma.j.cn112141-20200114-00039.
[9]	LI H, OUYANG Y, SADOVSKY E, et al. Unique microRNA signals in plasma exosomes from pregnancies complicated by preeclampsia[J]. Hypertension, 2020, 75(3):762-771. doi:10.1161/HYPERTENSIONAHA.119.14081.
[10]	ABDELZAHER W Y, MOSTAFA-HEDEAB G, BAHAA H A, et al. Leukotriene receptor antagonist,montelukast ameliorates L-NAME-induced pre-eclampsia in rats through suppressing the IL-6/Jak2/STAT3 signaling pathway[J]. Pharmaceuticals(Basel), 2022, 15(8):914. doi:10.3390/ph15080914.
[11]	LIU X, WANG W, BAI Y, et al. Identification of a genome-wide serum microRNA expression profile as potential noninvasive biomarkers for chronic kidney disease using next-generation sequencing[J]. J Int Med Res, 2020, 48(12):1220769033. doi:10.1177/0300060520969481.
[12]	CAI M, KOLLURU G K, AHMED A. Small molecule,big prospects:microRNA in pregnancy and its complications[J]. J Pregnancy, 2017, 201:6972732. doi:10.1155/2017/6972732.
[13]	HEMMATZADEH M, SHOMALI N, YOUSEFZADEH Y, et al. MicroRNAs:small molecules with a large impact on pre-eclampsia[J]. J Cell Physiol, 2020, 235(4):3235-3248. doi:10.1002/jcp.29286.
[14]	WU H Y, LIU K, ZHANG J L. LINC00240/miR-155 axis regulates function of trophoblasts and M2 macrophage polarization via modulating oxidative stress-induced pyroptosis in preeclampsia[J]. Mol Med, 2022, 28(1):119. doi:10.1186/s10020-022-00531-3.
[15]	EVORA P, SOARES R, BASSETTO S, et al. After thirty years,we still cannot understand why methylene blue is not a reference to treat vasoplegic syndrome in cardiac surgery[J]. Braz J Cardiovasc Surg, 2021, 36(3):406-411. doi:10.21470/1678-9741-2021-0955.
[16]	ITO H, MORISHITA R, NAGATA K I. Functions of rhotekin,an effector of rho GTPase,and its binding partners in mammals[J]. Int J Mol Sci, 2018, 19(7):2121. doi:10.3390/ijms19072121.
[17]	RAMDANI G, SCHALL N, KALYANARAMAN H, et al. cGMP-dependent protein kinase-2 regulates bone mass and prevents diabetic bone loss[J]. J Endocrinol, 2018, 238(3):203-219. doi:10.1530/JOE-18-0286.
[18]	BISWAS S, KOJONAZAROV B, HADZIC S, et al. IRAG1 deficient mice develop PKG1beta dependent pulmonary hypertension[J]. Cells, 2020, 9(10):2280. doi:10.3390/cells9102280.
[19]	FERNANDO I P S, KIRINDAGE K G I S, JAYASINGHE A M K, et al. Hot water extract of Sasa borealis (hack.) makino & shibata abate hydrogen peroxide-induced oxidative stress and apoptosis in kidney epithelial cells[J]. Antioxidants(Basel), 2022, 11(5):1013. doi:10.3390/antiox11051013.
[20]	ZHAO L, LI Y, YAO D, et al. Pharmacological basis for use of a novel compound in hyperuricemia:anti-hyperuricemic and anti-inflammatory effects[J]. Front Pharmacol, 2021, 12:772504. doi:10.3389/fphar.2021.772504.
[21]	STAFF A C. The two-stage placental model of preeclampsia:an update[J]. J Reprod Immunol, 2019:134-135. doi:10.1016/j.jri.2019.07.004.
[22]	WANG Y, LI B, ZHAO Y. Inflammation in preeclampsia:genetic biomarkers, mechanisms,and therapeutic strategies[J]. Front Immunol, 2022, 13:883404. doi:10.3389/fimmu.2022.883404.
[23]	SOCHA M W, MALINOWSKI B, PUK O, et al. The role of NF-κB in uterine spiral arteries remodeling,insight into the cornerstone of preeclampsia[J]. Int J Mol Sci, 2021, 22(2):704. doi:10.3390/ijms22020704.
[24]	MANN M, MEHTA A, ZHAO J L, et al. An NF-κB-microRNA regulatory network tunes macrophage inflammatory responses[J]. Nat Commun, 2017, 8(1):851. doi:10.1038/s41467-017-00972-z.

miR-155通过调控PKG1影响滋养细胞生物学功能并参与子痫前期的机制探讨

MiR-155 affects the biological functions of trophoblastic cells through regulating cGMP-dependent kinase 1 and is involved in the mechanism of preeclampsia

引用本文

RichHTML

PDF (PC)

可视化

摘要/Abstract

使用本文

图/表 16

参考文献 24

相关文章 15

编辑推荐

Metrics

本文评价

[1]	姜天佑, 李敏, 孙碧文, 李越洋, 邢丽静, 田晨. Let-7b诱导白血病相关巨噬细胞复极抑制AML的发展[J]. 天津医药, 2026, 54(3): 225-231.
[2]	杨晓芳, 贾新燕, 丰文君. miR-181a-5p通过HMGB1/NF-κB信号通路调控狼疮性肾炎小鼠肾小球系膜细胞增殖和凋亡[J]. 天津医药, 2026, 54(3): 232-237.
[3]	张婧, 魏玉英, 宁海虹, 韦红梅, 王嘉玮, 曹薇, 吴宾. DUSP9在2型糖尿病心肌病小鼠心肌损伤中的保护作用及其机制[J]. 天津医药, 2026, 54(3): 238-244.
[4]	王喆, 邱林, 马贲. 番茄来源胞外囊泡样颗粒对口腔鳞状细胞癌的作用效果研究[J]. 天津医药, 2026, 54(2): 145-150.
[5]	李志伟, 张会超, 杨凤鸣, 曾垂义. 基于miR-144-3p/MAPK1通路探讨红参总皂苷对扩张型心肌病小鼠心肌细胞凋亡的影响[J]. 天津医药, 2026, 54(1): 23-29.
[6]	赵兰君, 李良惠, 马馨, 巩娇娇, 郑臣辉, 石琳. 穿心莲内酯调控STAT3/GPX4通路对骨髓瘤细胞增殖和凋亡的影响[J]. 天津医药, 2026, 54(1): 8-13.
[7]	孔翠文, 路延双, 孙丽萍, 于芬芬. LncRNA SNHG14靶向miR-30a-5p对高糖诱导的足细胞损伤的影响[J]. 天津医药, 2025, 53(9): 903-909.
[8]	刘虹, 张玥玥, 王一琳, 王彩丽, 王晓敏, 毛敏, 李燕. MicroRNA-34a通过调控Wnt途径影响慢性淋巴细胞白血病进展的机制探讨[J]. 天津医药, 2025, 53(8): 785-790.
[9]	万艳波, 刘明, 王勇. 秦皮甲素调节HMGB1/RAGE信号通路对缺氧/复氧诱导的心肌细胞损伤的影响[J]. 天津医药, 2025, 53(8): 796-801.
[10]	刘海威, 杨洁, 王力, 蒙诗波, 唐旭松, 刘成仁, 王永旺. 木犀草素通过NFE2L2/x-CT/GPX4信号轴调控ROS水平抑制胶质母细胞瘤[J]. 天津医药, 2025, 53(7): 673-678.
[11]	蒋苏, 李东霞, 吕新翔, 崔艳红, 吕李婷. 基于PI3K/Akt/NF-κB信号通路探讨黄连素对特应性皮炎大鼠皮肤病理变化的治疗作用[J]. 天津医药, 2025, 53(7): 679-683.
[12]	韩建存, 周谊. 川陈皮素调节FAK/AKT信号通路对喉鳞状细胞癌细胞增殖和凋亡的影响[J]. 天津医药, 2025, 53(6): 561-565.
[13]	马春梅, 于鹏, 张其程, 杨磊, 李棣华, 谭建, 孟召伟. 异硫氰酸苄酯联合索拉非尼治疗未分化甲状腺癌机制探讨[J]. 天津医药, 2025, 53(5): 449-455.
[14]	余朝霞, 马贲, 邱林, 高倩, 尼娜. 基于网络药理学和实验验证探究鲍式层孔菌多酚的抗头颈鳞癌机制[J]. 天津医药, 2025, 53(5): 456-461.
[15]	李晨, 李占恩, 苏宏伟, 侯彩云, 董少文. KRT17调节Wnt/β-catenin信号通路对膀胱癌细胞增殖、凋亡及上皮间质转化的影响[J]. 天津医药, 2025, 53(5): 462-467.